Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis

Nobuhiko Kamada, Nagamu Inoue, Tadakazu Hisamatsu, Susumu Okamoto, Katsuyoshi Matsuoka, Toshiro Sato, Hiroshi Chinen, Kyong Su Hong, Takaya Yamada, Yumiko Suzuki, Tatsuo Suzuki, Noriaki Watanabe, Kanji Tsuchimoto, Toshifumi Hibi

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Nonpathogenic Escherichia coli strain Nissle1917 has been used as a probiotics in human inflammatory bowel disease; however, there are few reports examining its therapeutic effect on animal colitis models, and its therapeutic mechanisms remain unknown. The aim of this study was to elucidate the therapeutic effect and mechanism of Nissle1917 using murine acute and chronic colitis models. Methods: Two models were used. (1) Acute model: colitis was induced by administration of 1.3% dextran sodium sulfate for 7 days. Nissle1917 or phosphate-buffered saline were orally administered for 10 days. Mice were killed at day 10, and the colonic lesions were assessed macro- and microscopically. (2) Chronic model: IL-10-/- mice were treated with Nissle1917 or phosphate-buffered saline for 8 weeks. After 8 weeks of treatment, mice were killed to assess the colonic lesions macro- and microscopically. In the acute dextran sodium sulfate colitis model, viable, heat-killed, or genomic DNA of Nissle1917 was orally administered for 10 days, and the therapeutic effect was assessed. Results: In the acute model, Nissle1917 ameliorated body weight loss, disease activity index, and macro- and microscopic damage. In the chronic model, it also suppressed the mucosal inflammatory findings and histologic damages. Moreover, heat-killed Nissle1917 or its genomic DNA alone also ameliorated the acute DSS colitis and viable bacteria macro- and microscopically. Conclusions: Nonpathogenic E. coli strain Nissle1917 prevents both acute and chronic colitis, and its anti-inflammatory effect is exhibited not only by viable bacteria but also by heat-killed bacteria or its DNA.

Original languageEnglish
Pages (from-to)455-463
Number of pages9
JournalInflammatory Bowel Diseases
Volume11
Issue number5
DOIs
Publication statusPublished - 2005 May

Fingerprint

Colitis
Escherichia coli
Therapeutic Uses
Dextran Sulfate
Hot Temperature
Bacteria
DNA
Phosphates
Probiotics
Inflammatory Bowel Diseases
Interleukin-10
Weight Loss
Anti-Inflammatory Agents
Animal Models
Body Weight

Keywords

  • Dextran sodium sulfate colitis
  • IL-10-deficient mouse
  • Inflammatory bowel disease
  • Nissle1917
  • Probiotics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. / Kamada, Nobuhiko; Inoue, Nagamu; Hisamatsu, Tadakazu; Okamoto, Susumu; Matsuoka, Katsuyoshi; Sato, Toshiro; Chinen, Hiroshi; Hong, Kyong Su; Yamada, Takaya; Suzuki, Yumiko; Suzuki, Tatsuo; Watanabe, Noriaki; Tsuchimoto, Kanji; Hibi, Toshifumi.

In: Inflammatory Bowel Diseases, Vol. 11, No. 5, 05.2005, p. 455-463.

Research output: Contribution to journalArticle

Kamada, N, Inoue, N, Hisamatsu, T, Okamoto, S, Matsuoka, K, Sato, T, Chinen, H, Hong, KS, Yamada, T, Suzuki, Y, Suzuki, T, Watanabe, N, Tsuchimoto, K & Hibi, T 2005, 'Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis', Inflammatory Bowel Diseases, vol. 11, no. 5, pp. 455-463. https://doi.org/10.1097/01.MIB.0000158158.55955.de
Kamada, Nobuhiko ; Inoue, Nagamu ; Hisamatsu, Tadakazu ; Okamoto, Susumu ; Matsuoka, Katsuyoshi ; Sato, Toshiro ; Chinen, Hiroshi ; Hong, Kyong Su ; Yamada, Takaya ; Suzuki, Yumiko ; Suzuki, Tatsuo ; Watanabe, Noriaki ; Tsuchimoto, Kanji ; Hibi, Toshifumi. / Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. In: Inflammatory Bowel Diseases. 2005 ; Vol. 11, No. 5. pp. 455-463.
@article{2b0f7653d0da46798b43e667f5e5c1d1,
title = "Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis",
abstract = "Background: Nonpathogenic Escherichia coli strain Nissle1917 has been used as a probiotics in human inflammatory bowel disease; however, there are few reports examining its therapeutic effect on animal colitis models, and its therapeutic mechanisms remain unknown. The aim of this study was to elucidate the therapeutic effect and mechanism of Nissle1917 using murine acute and chronic colitis models. Methods: Two models were used. (1) Acute model: colitis was induced by administration of 1.3{\%} dextran sodium sulfate for 7 days. Nissle1917 or phosphate-buffered saline were orally administered for 10 days. Mice were killed at day 10, and the colonic lesions were assessed macro- and microscopically. (2) Chronic model: IL-10-/- mice were treated with Nissle1917 or phosphate-buffered saline for 8 weeks. After 8 weeks of treatment, mice were killed to assess the colonic lesions macro- and microscopically. In the acute dextran sodium sulfate colitis model, viable, heat-killed, or genomic DNA of Nissle1917 was orally administered for 10 days, and the therapeutic effect was assessed. Results: In the acute model, Nissle1917 ameliorated body weight loss, disease activity index, and macro- and microscopic damage. In the chronic model, it also suppressed the mucosal inflammatory findings and histologic damages. Moreover, heat-killed Nissle1917 or its genomic DNA alone also ameliorated the acute DSS colitis and viable bacteria macro- and microscopically. Conclusions: Nonpathogenic E. coli strain Nissle1917 prevents both acute and chronic colitis, and its anti-inflammatory effect is exhibited not only by viable bacteria but also by heat-killed bacteria or its DNA.",
keywords = "Dextran sodium sulfate colitis, IL-10-deficient mouse, Inflammatory bowel disease, Nissle1917, Probiotics",
author = "Nobuhiko Kamada and Nagamu Inoue and Tadakazu Hisamatsu and Susumu Okamoto and Katsuyoshi Matsuoka and Toshiro Sato and Hiroshi Chinen and Hong, {Kyong Su} and Takaya Yamada and Yumiko Suzuki and Tatsuo Suzuki and Noriaki Watanabe and Kanji Tsuchimoto and Toshifumi Hibi",
year = "2005",
month = "5",
doi = "10.1097/01.MIB.0000158158.55955.de",
language = "English",
volume = "11",
pages = "455--463",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis

AU - Kamada, Nobuhiko

AU - Inoue, Nagamu

AU - Hisamatsu, Tadakazu

AU - Okamoto, Susumu

AU - Matsuoka, Katsuyoshi

AU - Sato, Toshiro

AU - Chinen, Hiroshi

AU - Hong, Kyong Su

AU - Yamada, Takaya

AU - Suzuki, Yumiko

AU - Suzuki, Tatsuo

AU - Watanabe, Noriaki

AU - Tsuchimoto, Kanji

AU - Hibi, Toshifumi

PY - 2005/5

Y1 - 2005/5

N2 - Background: Nonpathogenic Escherichia coli strain Nissle1917 has been used as a probiotics in human inflammatory bowel disease; however, there are few reports examining its therapeutic effect on animal colitis models, and its therapeutic mechanisms remain unknown. The aim of this study was to elucidate the therapeutic effect and mechanism of Nissle1917 using murine acute and chronic colitis models. Methods: Two models were used. (1) Acute model: colitis was induced by administration of 1.3% dextran sodium sulfate for 7 days. Nissle1917 or phosphate-buffered saline were orally administered for 10 days. Mice were killed at day 10, and the colonic lesions were assessed macro- and microscopically. (2) Chronic model: IL-10-/- mice were treated with Nissle1917 or phosphate-buffered saline for 8 weeks. After 8 weeks of treatment, mice were killed to assess the colonic lesions macro- and microscopically. In the acute dextran sodium sulfate colitis model, viable, heat-killed, or genomic DNA of Nissle1917 was orally administered for 10 days, and the therapeutic effect was assessed. Results: In the acute model, Nissle1917 ameliorated body weight loss, disease activity index, and macro- and microscopic damage. In the chronic model, it also suppressed the mucosal inflammatory findings and histologic damages. Moreover, heat-killed Nissle1917 or its genomic DNA alone also ameliorated the acute DSS colitis and viable bacteria macro- and microscopically. Conclusions: Nonpathogenic E. coli strain Nissle1917 prevents both acute and chronic colitis, and its anti-inflammatory effect is exhibited not only by viable bacteria but also by heat-killed bacteria or its DNA.

AB - Background: Nonpathogenic Escherichia coli strain Nissle1917 has been used as a probiotics in human inflammatory bowel disease; however, there are few reports examining its therapeutic effect on animal colitis models, and its therapeutic mechanisms remain unknown. The aim of this study was to elucidate the therapeutic effect and mechanism of Nissle1917 using murine acute and chronic colitis models. Methods: Two models were used. (1) Acute model: colitis was induced by administration of 1.3% dextran sodium sulfate for 7 days. Nissle1917 or phosphate-buffered saline were orally administered for 10 days. Mice were killed at day 10, and the colonic lesions were assessed macro- and microscopically. (2) Chronic model: IL-10-/- mice were treated with Nissle1917 or phosphate-buffered saline for 8 weeks. After 8 weeks of treatment, mice were killed to assess the colonic lesions macro- and microscopically. In the acute dextran sodium sulfate colitis model, viable, heat-killed, or genomic DNA of Nissle1917 was orally administered for 10 days, and the therapeutic effect was assessed. Results: In the acute model, Nissle1917 ameliorated body weight loss, disease activity index, and macro- and microscopic damage. In the chronic model, it also suppressed the mucosal inflammatory findings and histologic damages. Moreover, heat-killed Nissle1917 or its genomic DNA alone also ameliorated the acute DSS colitis and viable bacteria macro- and microscopically. Conclusions: Nonpathogenic E. coli strain Nissle1917 prevents both acute and chronic colitis, and its anti-inflammatory effect is exhibited not only by viable bacteria but also by heat-killed bacteria or its DNA.

KW - Dextran sodium sulfate colitis

KW - IL-10-deficient mouse

KW - Inflammatory bowel disease

KW - Nissle1917

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=21044457648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044457648&partnerID=8YFLogxK

U2 - 10.1097/01.MIB.0000158158.55955.de

DO - 10.1097/01.MIB.0000158158.55955.de

M3 - Article

C2 - 15867585

AN - SCOPUS:21044457648

VL - 11

SP - 455

EP - 463

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 5

ER -